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Background: Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is rarely
curable. However, in view of the advent of new treatments, it is critical that patients at high risk for
recurrence are identified.
Methods: Patients undergoing LT for HCC at a single centre between 2002 and 2010 were reviewed and
data on clinical parameters and explant pathology were analysed to determine factors associated with
HCC recurrence. All necrotic and viable tumour nodules were included in explant staging. All patients
underwent LT according to the United Network for Organ Sharing (UNOS) Model for End-stage Liver
Disease (MELD) tumour exception policies.
Results: Liver transplantation was performed in 122 patients with HCC during this period. Rates of
recurrence-free survival in the entire cohort at 1 year and 3 years were 95% and 89%, respectively.
Thirteen patients developed HCC recurrence at a median of 14 months post-LT. In univariate analysis the
factors associated with HCC recurrence were bilobar tumours, vascular invasion, and stage exceeding
either Milan or University of California San Francisco (UCSF) Criteria. Multivariate analysis showed
pathology outside UCSF Criteria was the major predictor of recurrence; when pathology outside UCSF
Criteria was found in combination with vascular invasion, the predicted 3-year recurrence-free survival
was only 26%.
Conclusions: Explant pathology can be used to predict the risk for recurrent HCC after LT, which may
allow for improved adjuvant and management strategies.
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Introduction
Liver transplantation (LT) is widely accepted as an effective treat-
ment for early-stage hepatocellular carcinoma (HCC). In 2002 the
United Network for Organ Sharing (UNOS) revised the liver
organ allocation process in the USA to include the Model for
End-stage Liver Disease (MELD) score, with an important built-in
exception which gave an advantage to patients on the waiting list
with HCC that met the Milan Criteria.1 In recent years, some
UNOS regions have also allowed LT through the MELD exception
process for patients with more advanced malignancy, provided
they were able to undergo downstaging to bring their tumour
burden to within the Milan Criteria.2 The inherent advantage
provided by the MELD exception process, along with increasing
enthusiasm for LT in more advanced tumours, has been accom-
panied by an increase in the number of patients with HCC now
This paper was presented at the American Hepato-Pancreato-Biliary
Association 11th Annual Meeting, Miami, FL, USA.
DOI:10.1111/j.1477-2574.2011.00342.x HPB
HPB 2011, 13, 626–632 © 2011 International Hepato-Pancreato-Biliary Association
listed for LT and an increase in the number of transplants per-
formed for HCC. In 2010, 1221 of 5516 (22%) deceased donor LTs
in the USA were performed for HCC.3
Patients undergoing LT for HCC face an obvious risk for
tumour recurrence. The risk for recurrence, as well as the rate of
progression of recurrent tumours, is thought to be accentuated by
immunosuppressive medications.4 An important tenet of LT is to
balance the risk for tumour recurrence against the value of the
organ, taking into consideration the needs and wishes of the
cancer patient and the limited number of available donor organs.
The Milan Criteria (Table 1) are, in fact, widely accepted as rep-
resenting a pre-transplant measure of the risk for tumour recur-
rence because HCC cases that meet these criteria are associated
with a low risk for recurrent HCC after LT.5 Other methods can
also be used to predict the risk for HCC recurrence after LT,
including the presence of vascular invasion in explant tumours,
tumour grade and even other numerical staging systems such as
the University of California San Francisco (UCSF) Criteria or the
Up-to-Seven rule.6 As the transplant environment changes,
however, the factors that may predict recurrence need to be con-
tinually evaluated to help guide organ allocation and clarify the
risks to the patient after LT.
The stratification of patient risk for post-transplant recurrence
of HCC may have value beyond simple prognostication. Identifi-
cation of high-risk groups may allow early conversion to alterna-
tive immunosuppression regimens, such as the use of mTOR
inhibitors,7 or may allow for appropriate enrolment in trials or
protocols of adjuvant therapy, such as the use of the multi-kinase
inhibitor sorafenib.8 In the current study, data for a population of
patients who underwent LT for HCC over an 8.5-year period were
analysed to determine contemporary risk factors for tumour
recurrence. Of note, our centre is in UNOS Region 5, which has
longer wait times for LT than most UNOS regions.9
Materials and methods
With the approval of the Cedars–Sinai Medical Center’s institu-
tional review board, data were obtained from records of all
patients who underwent deceased donor LT for HCC at our centre
between 1 January 2002 and 1 July 2010. Clinical parameters
included patient demographics, time on the wait list after diagno-
sis of HCC, cancer treatments utilized while on the wait list
(bridging treatments), and whether or not the patient underwent
downstaging to meet the Milan Criteria, which, in turn, requires
formal review by the UNOS Region 5 Regional Review Board.
Imaging records were reviewed to determine the most recent
radiologic stage prior to LT, as well as the timing and site of any
recurrent tumour after LT.
Pathologic staging of liver explants was performed by reviewing
pathology reports. All viable and necrotic nodules were consid-
ered to represent tumours. The size, number and distribution of
tumours (bilobar or unilobar) were noted, as was the presence of
microvascular or macrovascular invasion. Based on the size and
number of tumours, each explant was staged into one of three
categories: (i) within the Milan Criteria; (ii) outside the Milan
Criteria but within the expanded UCSF Criteria, and (iii) outside
the expanded UCSF Criteria (Table 1). All nodules in the patho-
logic staging of explants were assessed for two reasons: firstly,
some reports from early in the study period did not state whether
nodules were necrotic or viable and thus pathologic staging would
allow the inclusion of these patients, and, secondly, this type of
cumulative staging is more reflective of the multiple sequential
bridging treatments patients often receive while on the wait list. Of
note, hepatic artery chemoembolization (HACE) was used almost
exclusively for bridging during this time period. The type of all-
inclusive post-treatment staging used in this study would not be
reliable if our centre had used thermal ablative techniques for
bridging as this modality creates a zone of necrosis that is larger
than the original tumour.With HACE, however, necrotic nodules
should be reasonably representative of the original tumour.
Statistical analysis
Direct comparison was performed between patients with and
without HCC recurrence using a variety of paired analyses. Clini-
cal and pathologic factors in these groups were compared using
Student’s t-test (for continuous data), Fisher’s exact test (for cat-
egorical data) and Wilcoxon rank sum test (for non-parametric
ordinal data).
To create a model that would also account for variable time of
follow-up, recurrence-free survival was analysed using Kaplan–
Meier product limit estimators and Cox proportional hazard
models to compute risk in the form of hazard ratios (HRs). Dif-
ferences in survival times between strata were assessed with the
log-rank test. Individual risk factors were considered first in
single-variable models using data from all cases.Multiple-variable
analysis using forward stepwise selection methods with inclusion/
exclusion criteria and a P-value of <0.05 was used to identify the
Table 1 Staging criteria for liver transplantation
Number of lesions Milan Criteria UCSF Standard Criteria UCSF Expanded Criteria
1 5 cm 6.5 cm 8 cm
2 or 3 3 cm 4.5 cma 5 cma
4 or 5 N/A N/A 3 cma
aMaximum total tumour diameter 8 cm.
UCSF, University of California San Francisco; N/A, not applicable.
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set of factors predictive of disease recurrence. Relevant interaction
terms were also considered. The proportional hazards assumption
was tested graphically and model diagnostics (Martingale and
Shoenfeld residuals) were used to assess model adequacy.
Statistical analysis was performed using sas Version 9.1 (SAS
Institute, Inc., Cary, NC, USA). All statistical tests were two-sided
and P-values of <0.05 were considered to indicate statistical sig-
nificance.
Results
The characteristics of the study cohort (n = 122) are presented in
Table 2. No patient was lost to follow-up and all patients under-
went routine imaging at 3–6-month intervals until 3 years post-
LT. The median length of follow-up in the study cohort was 32.7
months (range: 6–96 months). Mean  standard error (SE)
overall survival in the entire group at 1 and 3 years was 92.2 
2.5% and 84.8  3.7%, respectively. Disease recurrence was
observed in 13 cases (11%) at a median of 13.7 months (range:
5.0–44.8 months). Based on Kaplan–Meier methods, the mean 
SE recurrence-free survival time was 41.1 1.1 months, and 94.6
 2.2% and 89.2  3.1% of patients survived without disease
progression to 1 and 3 years, respectively.
A direct comparison of patients with and without recurrent
HCC is shown in Table 3. Explant pathology factors significantly
associated with an increased risk for HCC recurrence after LT
included: (i) pathology beyond the Milan Criteria; (ii) pathology
beyond the expanded UCSF Criteria; (iii) more than three
tumours on explant; (iv) the presence of vascular invasion, and (v)
bilobar tumours. None of the clinical or wait list parameters were
significantly associated with HCC recurrence. Specifically, higher
alpha-fetoprotein (AFP) levels and the need for downstaging to
within the Milan Criteria (n = 11) were not associated with higher
risk for recurrence.
Significant predictors of disease recurrence were also deter-
mined using Cox HR modelling. An analysis of individual vari-
ables showed that these same five pathologic criteria were all
associated with increased risk for HCC recurrence (Table 4): (i)
stage beyond the Milan Criteria; (ii) stage beyond the expanded
UCSF Criteria; (iii) more than three tumours; (iv) presence of
vascular invasion, and (v) bilobar lesions on pathology. Clinical
and wait list parameters, including age at LT, pre-LT AFP, UCSF
downstaging and use of pre-LT bridging treatments, were not
predictive of time to disease recurrence. Pre-LT waiting time of
6 months was marginally associated with a higher risk for recur-
rence (P = 0.063). Recurrence-free survival of 100% was observed
among subjects meeting the Milan Criteria or in whom the
tumour was not viable on pathologic examination; therefore sta-
tistical analysis of these two variables on recurrence-free survival
times is unavailable.
Of the 68 patients whose disease met the Milan Criteria, none
experienced disease recurrence (100% recurrence-free survival
was observed). Multivariable Cox proportional hazard modelling
of survival times was performed for the 54 patients in whom
disease exceeded the Milan Criteria to determine which set of
factors is most predictive of disease recurrence. Using forward
stepwise selection methods, UCSF Criteria (HR = 8.11, 95% con-
fidence interval [CI] 2.10–1.36; P = 0.002) and presence of vascu-
lar invasion of the tumour (HR = 3.28, 95% CI 1.02–10.51; P =
0.046) retained significant association with shorter recurrence-
free survival times in patients in whom disease exceeded theMilan
Criteria. Table 5 presents the 1- and 3-year disease-free survival
rates across the Milan and UCSF Criteria in patients with and
without vascular invasion of the tumour. In patients with explant
pathology beyond the UCSF Criteria, the group without associ-
ated vascular invasion achieved an expected 3-year disease-free
survival of 67%, but this dropped to 27% in the presence of
associated vascular invasion. This is further evidenced by the
Kaplan–Meier disease-free survival curves for all groups (Fig. 1).
Discussion
The recurrence of HCC after LT is generally considered an
ominous finding.We have demonstrated in this report that several
factors, primarily evidenced by explant pathology, can be used to
stratify patients into high- and low-risk groups for recurrence
(summarized in Table 6). In our series, we saw no recurrence of
HCC in patients with explant pathology within theMilan Criteria.
Patients with explant pathology beyond the Milan Criteria but
within the expanded UCSF Criteria also had a low risk for recur-
rence, with 3-year disease-free survival of 80–88%. By contrast,
Table 2 Characteristics of the study cohort (n = 122)
Variable Data
Age, years, mean  SD 58.3  6.8
Waiting time, months, mean  SD 5.0  3.5
Pre-transplant AFP > 25 ng/ml, n (%) 38a (38%)
Pre-transplant bridging therapy, n (%) 88 (72%)
Pathology staging
Within Milan Criteria 68 (56%)
Exceeding Milan Criteria 54 (44%)
Exceeding Milan, within expanded UCSF Criteria 33 (27%)
Exceeding expanded UCSF Criteria 21 (17%)
Max tumour size > 3 cm 56b (48%)
Tumour count > 3 25 (20%)
Presence of vascular invasion 19c (18%)
Bilobar
On imaging and pathology 45c (39%)
On pathology alone 33d (31%)
Regional Review for Downstaging 11 (9%)
Viable tumour on explant 60e (73%)
a–eData available for a101, b117, c106, d105 and e82 cases only.
SD, standard deviation; AFP, alpha-fetoprotein; UCSF, University of
California San Francisco.
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Table 3 Comparison of characteristics of patients in the recurrence and non-recurrence groups
Variable Recurrence No recurrence P-value
(n = 13) (n = 109)
Age, years, mean (range) 58.5 (51.2–66.6) 58.3 (39.3–74.6) 0.921 h
Waiting time, months (mean, range) 6.1 (0.9–17.3) 4.9 (0.1–17.0) 0.238 h
Pre-transplant AFP, ng/ml, mean (range) 518a (4–2730) 239d (2–11 650) 0.118 j
Pre-transplant bridging treatment 10 77% 78 72% 1.000 i
Pathology staging
Within Milan Criteria 0 0% 68 100% N/A i
Overall exceeding Milan Criteria 13 100% 41 38% <0.001 i
Exceeding Milan, within expanded UCSF Criteria 4 31% 29 27% 0.747 i
Exceeding expanded UCSF Criteria 9 69% 12 11% <0.001 i
Tumour size
Maximal size, cm, mean (range) 3.7 (2.2–6.5) 3.0e (0.9–6.5) 0.081 h
Tumour count
Tumour count, mean (range) 5.2 (3–9) 2.0 (0–9) <0.001 h
>3 tumours 12 92% 13 12% <0.001 i
Presence of vascular invasion 6a 50% 13f 14% 0.011 i
Bilobar
On imaging and pathology 8a 67% 37e 35% 0.057 i
On pathology alone 7b 64% 26f 35% 0.034 i
Regional Review for Downstaging 2 15% 9 8% 0.336 i
Viable 5c 100% 55g 71% 0.317 i
a–gData available for only a12, b11 and c5 of the recurrence cases or for d89, e104, f94 and g77 of the no-recurrence cases.
h–jP-values computed via hStudent's t-test, iFisher's exact test or jWilcoxon rank sum test.
AFP, alpha-fetoprotein; UCSF, University of California San Francisco.
Table 4 Cox proportional hazard modelling of recurrence-free survival times in the full study cohort
Variable Univariate analysis
P-value Hazard ratio (95% CI)
Age >60 years 0.438 1.54 (0.52–4.58)
Waiting time 6 months 0.063 2.91 (0.94–9.00)
Pre-transplant AFP >25 ng/ml 0.148 2.34 (0.74–7.39)
Pre-transplant bridging therapy 0.451 1.65 (0.45–5.99)
Pathology staging
Exceeds Milan Criteria 0.991 Not estimated
Exceeds expanded UCSF Criteria <0.001 13.83 (4.24–45.12)
Exceeds Milan, within expanded UCSF Criteria 0.728 1.23 (0.38–4.00)
Maximal tumour size > 3 cm 0.110 2.62 (0.81–8.50)
Tumour count > 3 <0.001 59.13 (7.67–456)
Presence of vascular invasion 0.008 4.70 (1.51–14.63)
Bilobar
On imaging and pathology 0.064 3.12 (0.94–10.37)
On pathology alone 0.028 4.00 (1.17–13.71)
Regional Review for Downstaging 0.337 2.10 (0.46–9.50)
Viable tumour on explant 0.995 Not estimated
95% CI, 95% confidence interval; AFP, alpha-fetoprotein; UCSF, University of California San Francisco.
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patients with pathologic staging outside the expanded UCSF Cri-
teria and with vascular invasion had a risk for recurrence of 73%
at 3 years (Table 5). In univariate analysis, several additional
pathologic factors, including bilobar tumour distribution, were
associated with HCC recurrence, whereas waiting time for LT of
6 months after HCC diagnosis was marginally associated with
risk for recurrence (Table 4). Wait list variables such as AFP level
and the need to downstage the tumour to meet the Milan Criteria
were not associated with risk for recurrence, but this may reflect
the small sample size. Other studies have demonstrated an
increased risk for post-LT recurrence with high pre-transplant
AFP levels.10
This study has several obvious limitations. Firstly, in many
patients, follow-up time was relatively short and the disease may
not have had time to recur. This is accounted for by the time-based
Cox proportional modelling, but longer follow-up of the more
recent cohort will be helpful. Secondly, we used an all-inclusive
staging system which is not commonly used. All viable and
necrotic nodules were counted in pathologic staging. Although
this type of staging is not standard, we feel that it gives a better
picture of the total tumour burden in the liver over time and
lessens the error that might be introduced by sampling error in
any given necrotic tumour. To further account for this cumulative
staging, the expanded UCSF Criteria were used as the break point
in staging.11 A final limitation of this study concerns the small size
of the sample of recurrent tumours, but the type of detailed
information we sought is only available in a single-centre study
such as this.
One of the most important objectives of this and similar
reports is to help guide the management of the post-LT patient
with respect to both monitoring for tumour recurrence and
employing preventative strategies. Our data suggest that the
patient with explant pathology within the Milan Criteria has a
negligible risk for tumour recurrence and thus these patients can
be monitored with less stringency post-transplant. This has impli-
cations for cost savings and for reducing the patient’s exposure to
radiation and contrast-enhancing agents. However, this study also
suggests that the patient with vascular invasion and either bilobar
tumours or an overall explant stage beyond the expanded UCSF
Criteria faces an exceedingly high risk for tumour recurrence.
These patients should be followed with frequent imaging and AFP
Table 5 Kaplan–Meier recurrence-free survival proportions at 1 and 3 years
Milan UCSFa Vascular invasion n 1-year survival 3-year survival
Rate (SE) Rate (SE)
Within N/A N/A 68 100% (0%) 100% (0%)
Exceeding Within Absent 23 100% (0%) 87.5% (8.3%)
Present 6 100% (0%) 80.0% (17.9%)
Exceeding Absent 11 80.0% (12.7%) 66.7% (16.1%)
Present 7 53.6% (20.1%) 26.8% (21.4%)
aExpanded UCSF Criteria.
UCSF, University of California San Francisco; SE, standard error; N/A, not applicable.
0
0 1 2 3
25
50
75
100
P
er
ce
nt
ag
e 
di
se
as
e-
fr
ee
Time to recurrence, years
Within Milan Criteria
Exceeding Milan, within UCSF Criteria, LVI−
Exceeding Milan, within UCSF Criteria, LVI+
Exceeding Milan and UCSF Criteria, LVI−
Exceeding Milan and UCSF Criteria, LVI+
Figure 1 Kaplan–Meier curves for disease-free survival in all groups. LVI, lymphovascular invasion
Table 6 Cedars–Sinai risk factors for recurrence of hepatocellular
carcinoma after liver transplant
Factor
Pathology outside UCSF Criteriaa
Vascular invasiona
Pathology outside Milan Criteria
More than three tumours
Bilobar tumours
Waiting time  6 months
aSignificant in both univariate and multivariate analysis.
UCSF, University of California San Francisco.
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monitoring. In addition, high-risk patients should be considered
for two additional therapeutic manoeuvres: (i) alteration in
immunosuppression, either by using the lowest tolerable cal-
cineurin inhibitor regimen or by transitioning to an mTOR
inhibitor, such as sirolimus or everolimus, and (ii) enrolment in
protocols or trials aimed at preventing or delaying recurrence,
such as by using the multi-kinase inhibitor sorafenib, which has
recently been shown to have activity against HCC.12 In our pro-
gramme, we have now adopted this low risk/high risk stratifica-
tion in order to determine the surveillance protocol and the ideal
immunosuppressive regimen for each individual patient.
One finding in the current study that may raise concern is that
44% of our patients were found to have explant pathology beyond
the Milan Criteria, although the protocol for transplant eligibility
required the patient to meet radiologic Milan Criteria during the
pre-transplant period. This may be partly explained by radio-
graphic understaging and partly by the all-inclusive pathology
system we utilized. All patients undergoing LT for HCC according
to the MELD exception system are required to undergo imaging
every 3 months, the results of which are reported to UNOS. It is
important to note, however, that pre-LT radiographic staging
includes only viable tumours, which on current magnetic reso-
nance imaging and computed tomography scans are interpreted
as tumours with hypervascularity. Treated non-viable tumours are
not counted in the pre-transplant staging system. Our post-
transplant staging system included both necrotic and viable
tumours, and in this way reflects the cumulative effect of repeated
treatments over the lifespan of the liver. As demonstrated by the
results, this form of all-inclusive explant staging is fairly accurate
in predicting risk for recurrent tumour after transplant. These
findings also suggest that the risk for recurrent HCC may not be
adequately predicted by the snapshot approach currently used by
the transplant community, in which transplant candidacy is main-
tained at each evaluation interval provided the staging of viable
tumours is within the Milan Criteria. Equally important in strati-
fying risk are data on whether the patient requires repeated inter-
ventions while on the wait list or whether he or she has a sum of
treated tumours that surpass the expanded UCSF Criteria.
The findings of this single-centre report are not unique, but,
rather, add to the growing body of literature on the phenotype of
patients undergoing deceased donor LT for HCC in the USA, and
in particular in UNOS Region 5. This region has one of the longest
wait list times for LT in the country, which results in the wide-
spread use of multiple wait list bridging modalities. As in our
series, several other larger reports have similarly demonstrated
that the risk for HCC recurrence after LT is increased in patients
found to have tumours that fall outside the Milan or UCSF Cri-
teria or which involve vascular invasion.13,14 Our data suggest,
however, that the only group at prohibitive risk for recurrence is
the group with all-inclusive explant pathology beyond the
expanded UCSF Criteria and with vascular invasion. Recurrence-
free survival at 3 years was only 27% in this group. Patients with
less advanced tumour size or number, even in the presence of
vascular invasion, achieved survival rates that were quite accept-
able. Based on our data, a more reliable pre-LT indicator of vas-
cular invasion would eliminate most recurrences, even in patients
with long wait times and in advanced tumour staging groups. The
ideal surrogate marker for vascular invasion remains elusive; we
propose that, in select patients, direct tissue acquisition may be a
useful although perhaps risky way to ensure the best chance of
survival and the best use of organs.
In summary, this report provides important information for
stratifying post-LT patients into groups with low and high risk for
recurrent HCC. Low-risk patients are those with explant staging
that falls within the Milan Criteria or with complete tumour
necrosis. High-risk patients are those with cumulative tumour
staging that exceeds the expanded UCSF Criteria, and this risk is
especially high if those patients have vascular invasion on explant.
These data indirectly support the continued acceptance of the
current process of downstaging patients prior to transplant as
long as they meet the expanded UCSF Criteria at the time of
treatment, as we saw few recurrences in patients who were for-
mally downstaged and we found that explant pathology within the
expanded UCSF Criteria was associated with a low overall risk for
recurrence.
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